Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States
Ronald C. Chen,Rupali Fuldeore,Alexandra Greatsinger,Zsolt Hepp,Qing Liu,Phoebe Wright,Bin Xie,Hongbo Yang,Christopher Young,Adina Zhang,Lisa Mucha
DOI: https://doi.org/10.1016/j.urolonc.2024.11.010
IF: 2.954
2024-12-16
Urologic Oncology Seminars and Original Investigations
Abstract:Background Given the changing treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC), this study aimed to describe real-world treatments, overall survival (OS), health care resource utilization (HCRU), and costs among US patients with la/mUC receiving first-line therapy. Methods This retrospective study was conducted using 100% Medicare claims data (2015–2020). Patients with la/mUC were selected; initiation of first-line therapy was the index date. Treatments and OS were assessed during follow-up (index date to the earliest of end of data availability, health plan coverage, or death). All-cause HCRU and costs (2021 USD) were assessed during the first-line treatment period (index date to the earliest of first-line discontinuation, switch to second-line therapy, end of follow-up, or death). Outpatient pharmacy costs were not included. All-cause OS from start of first-line therapy was estimated using the Kaplan–Meier approach. The HCRU, cost, and OS analyses were stratified by 3 index treatment groups—platinum-based chemotherapy, non–platinum-based chemotherapy, and programmed cell death protein 1/ligand 1 (PD-1/L1) inhibitor monotherapy—and adjusted for baseline characteristics. Results Of 9,939 patients included, 77.1% were men and mean age was 76 years. In total, 5,050 (50.8%) received platinum-based chemotherapy, 1,361 (13.7%) received non–platinum-based chemotherapy, and 3,242 (32.6%) received PD-1/L1 inhibitor monotherapy for first-line la/mUC. Median OS was 12.9, 12.9 ( P = 0.960), and 9.0 months ( P 99%) patients had ≥ 1 outpatient visit during the treatment period; mean number of visits per patient was 13.1 with platinum-based chemotherapy, 10.5 with non–platinum-based chemotherapy, and 18.3 with PD-1/L1 inhibitor monotherapy. In general, HCRU was significantly lower for patients receiving PD-1/L1 inhibitor monotherapy versus platinum-based chemotherapy. However, costs were significantly higher with PD-1/L1 inhibitor monotherapy versus platinum-based chemotherapy. Mean total monthly cost per patient was 8,982 for non–platinum-based chemotherapy, and $18,147 for PD-1/L1 inhibitor monotherapy. Conclusions From 2015 to 2020, patients with la/mUC had substantial HCRU and costs and short survival, regardless of first-line treatment. More effective therapies were needed to prolong survival and reduce the economic burden of la/mUC.
oncology,urology & nephrology